Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib and Radiotherapy in EGFR-mutated NSCLC Brain Metastases
NCT04643847Phase 2Unknown
- Sponsor
- Hangzhou First People's Hospital
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hangzhou First People's Hospital. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04643847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643847.